A 5★ new review of the GLP-1 drugs, what they have achieved, and where the field is headed with so many new molecules and combinations
@thelancet.com
thelancet.com/journals/lan...
A Swapless episode! But had a great time in listening to it
In the last #KidneyKompass @brendonneuen.bsky.social chats with Sophia Zoungas podcasts.apple.com/ca/podcast/k... on the SURPASS data
G-force FTW @christosargyrop.bsky.social @rnflex.bsky.social
Hey @brianrifkin.bsky.social if sema is captopril what would you call dulaglutide? 😏
Loved watching @kidneyrebel.bsky.social grand rounds at @nu-nephrology.bsky.social!!
Thank you for the PKD mega blocks shout out #nephjc (1), happy to be at the right overlap in my Venn diagram (2), and trying to build toward a medical specialty in a hill (3)
www.youtube.com/watch?v=RlTC...
Huge congratulations Mike and Lonnie.
IMJ June 2025 #OpenAccess
Editor's choice (original article): Smoking and kidney transplantation wait listing
bit.ly/4kFslsJ
@theracp.bsky.social
@sunilbadve.bsky.social
IMJ June 2025 #FreeAccess
Editorial: Smokers and kidney transplantation assessment: a question of risk or equity?
bit.ly/3FUCH8Q
@theracp.bsky.social
@sunilbadve.bsky.social
It's been a long journey but today we can share the methods and rationale for the #ACHIEVEtrial (Spiro vs placebo for patients with kidney failure receiving maintenance dialysis) and tomorrow we share the results at #era25
journals.sagepub.com/doi/10.1177/...
Save the date for Kidney Supportive Care Masterclass 2025 and Serious Illness Conversations Workshop. Open to nephrologists, nephrology trainees and nurse practitioners. Separate registrations for the Masterclass (forms.office.com/r/L90B6DrscS) and the Workshop (email in the image).
This one is a no-brainer
Become an FASN @asnkidney.bsky.social
My pitch at the last #KidneyWk
youtu.be/9uzq2KIjuNk?...
#NephSky
(h/t @sunilbadve.bsky.social )
📢 New Systematic Review & Meta-Analysis in
@kireports.bsky.social 📢
We evaluated the effects of iron therapy on clinical outcomes in chronic kidney disease (CKD), analyzing 45 randomized trials. A summary of our findings: 🧵
www.kireports.org/article/S246...
RAASi are not nephrotoxic text
The UKKA AKI report is out, h/t @beckybonfield.bsky.social
@ukkidney.org
www.ukkidney.org/sites/defaul... (PDF)
Incl.
- Don’t call RAASi nephrotoxic
- Don’t delay contrast imaging
- Sick day rules are mostly 🐴 💩
In people with T2D, effects of GLP1-RA on CV, kidney & mortality outcomes are consistent irrespective of SGLT2i
Our meta-analysis of the 3 GLP1RA diabetes clinical outcome trials with the largest prevalent use of SGLT2i in @ahajournals.bsky.social Circulation
www.ahajournals.org/doi/10.1161/...
We did the trial. Now in the era of SGLT2i and GLP-1 RA, it’s a distant memory 😂
Clear ⏬ with GLP-1RA by ~15% for all clinical outcomes including:
Kidney failure ✅
Major CV events ✅
Heart failure ✅
CV death ✅
All-cause death ✅
Updated systematic review/meta-analysis of 11 trials ~85,000 participants, with & without diabetes
Now in Lancet D&E: www.thelancet.com/journals/lan...
Sharing the free access link here (for 50 days only) authors.elsevier.com/a/1k9u77tNuc...
Wishing the Elsevier editors who desk-accepted this all the best for their next career moves.
doi.org/10.1016/j.ij...
QR code for pack 3
Good morning!
Nov 15 AM update:
The 3rd Nephrology pack is well known its way: go.bsky.app/2yLiYN4
Second pack go.bsky.app/N27Kzri
First pack: go.bsky.app/H4td28C
Hypertension Nerds go.bsky.app/KBLojr
Kidney/HT Journals go.bsky.app/2BG7wKr
Please reply or DM me to be added!